Kimberly Blackwell - 03 Jan 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Director
Signature
By: /s/ Melissa B. Epperly, Attorney-in-Fact for Kimberly Blackwell
Issuer symbol
ZNTL
Transactions as of
03 Jan 2022
Net transactions value
-$35,940
Form type
4
Filing time
05 Jan 2022, 16:49:28 UTC
Previous filing
02 Dec 2021
Next filing
20 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Options Exercise $47,800 +1,000 +20% $47.80 6,000 03 Jan 2022 Direct F1
transaction ZNTL Common Stock Sale $83,740 -1,000 -17% $83.74 5,000 03 Jan 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Options Exercise $0 -1,000 -2.6% $0.000000 38,000 03 Jan 2022 Common Stock 1,000 $47.80 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option exercise and sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 20, 2021.
F2 The options vest and become exercisable in substantially equal monthly installments over the 36 months following the date of grant on July 1, 2020.